BACKGROUND AND PURPOSE: Intraventricular extension of hemorrhage is a predictor of poor outcome in intracerebral hemorrhage, and iron overload contributes to brain injury after intracerebral hemorrhage. The current study investigated the role of iron in ventricular dilatation and neuronal death in a rat model of intraventricular hemorrhage (IVH). METHODS: There were 2 parts in this study. First, male Sprague-Dawley rats had a 200-μL injection of either autologous blood or saline into the right lateral ventricle and were euthanized at different time points. Rats had MRI and brains were used for Western blot analysis, immunohistochemistry, histology, and brain tissue nonheme iron measurements. Second, rats had IVH and were treated with deferoxamine or vehicle, and rats were euthanized 4 weeks later for brain tissue loss and lateral ventricle size measurements. RESULTS: IVH resulted in brain iron accumulation, bilateral enlargement of the lateral ventricles, and hippocampal brain tissue loss. Iron accumulation was associated with upregulation of heme oxygenase-1 and ferritin. Systemic deferoxamine treatment reduced IVH-induced ventricular enlargement (eg, day 28: 32.7±10.6 vs 43.8±9.7 mm(3) in vehicle-treated group, n=8 to 9; P<0.05) and hippocampal brain tissue loss (hippocampal volume: 89.0±2.7 vs 85.2±4.1 mm(3) in the vehicle-treated group; P<0.05). CONCLUSIONS: Iron has a role in brain injury after IVH. Deferoxamine may be a therapy for patients with IVH or intraventricular extension after intracerebral hemorrhage.
BACKGROUND AND PURPOSE: Intraventricular extension of hemorrhage is a predictor of poor outcome in intracerebral hemorrhage, and iron overload contributes to brain injury after intracerebral hemorrhage. The current study investigated the role of iron in ventricular dilatation and neuronal death in a rat model of intraventricular hemorrhage (IVH). METHODS: There were 2 parts in this study. First, male Sprague-Dawley rats had a 200-μL injection of either autologous blood or saline into the right lateral ventricle and were euthanized at different time points. Rats had MRI and brains were used for Western blot analysis, immunohistochemistry, histology, and brain tissue nonheme iron measurements. Second, rats had IVH and were treated with deferoxamine or vehicle, and rats were euthanized 4 weeks later for brain tissue loss and lateral ventricle size measurements. RESULTS:IVH resulted in brain iron accumulation, bilateral enlargement of the lateral ventricles, and hippocampal brain tissue loss. Iron accumulation was associated with upregulation of heme oxygenase-1 and ferritin. Systemic deferoxamine treatment reduced IVH-induced ventricular enlargement (eg, day 28: 32.7±10.6 vs 43.8±9.7 mm(3) in vehicle-treated group, n=8 to 9; P<0.05) and hippocampal brain tissue loss (hippocampal volume: 89.0±2.7 vs 85.2±4.1 mm(3) in the vehicle-treated group; P<0.05). CONCLUSIONS:Iron has a role in brain injury after IVH. Deferoxamine may be a therapy for patients with IVH or intraventricular extension after intracerebral hemorrhage.
Authors: H Tsukamoto; W Horne; S Kamimura; O Niemelä; S Parkkila; S Ylä-Herttuala; G M Brittenham Journal: J Clin Invest Date: 1995-07 Impact factor: 14.808
Authors: Takehiro Nakamura; Richard F Keep; Ya Hua; Timothy Schallert; Julian T Hoff; Guohua Xi Journal: J Neurosurg Date: 2004-04 Impact factor: 5.115
Authors: Tim Lekic; Damon Klebe; Roy Poblete; Paul R Krafft; William B Rolland; Jiping Tang; John H Zhang Journal: Curr Med Chem Date: 2015 Impact factor: 4.530
Authors: Jennifer M Strahle; Thomas Garton; Ahmad A Bazzi; Harish Kilaru; Hugh J L Garton; Cormac O Maher; Karin M Muraszko; Richard F Keep; Guohua Xi Journal: Neurosurgery Date: 2014-12 Impact factor: 4.654
Authors: Dewei Guo; D Andrew Wilkinson; B Gregory Thompson; Aditya S Pandey; Richard F Keep; Guohua Xi; Ya Hua Journal: Transl Stroke Res Date: 2016-11-28 Impact factor: 6.829
Authors: Andreas H Kramer; Craig N Jenne; David A Zygun; Derek J Roberts; Michael D Hill; Jessalyn K Holodinsky; Stephanie Todd; Paul Kubes; John H Wong Journal: J Cereb Blood Flow Metab Date: 2015-04-08 Impact factor: 6.200